Display options
Cite
Miao XP, Ouyang Q, Li HY, et al. Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: A systematic review and meta-analysis. Curr Ther Res Clin Exp. 2008;69(3):181-91doi: 10.1016/j.curtheres.2008.06.009.
Miao, X. P., Ouyang, Q., Li, H. Y., Wen, Z. H., Zhang, D. K., & Cui, X. Y. (2008). Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: A systematic review and meta-analysis. Current therapeutic research, clinical and experimental, 69(3), 181-91. https://doi.org/10.1016/j.curtheres.2008.06.009
Miao, Xin-Pu, et al. "Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: A systematic review and meta-analysis." Current therapeutic research, clinical and experimental vol. 69,3 (2008): 181-91. doi: https://doi.org/10.1016/j.curtheres.2008.06.009
Miao XP, Ouyang Q, Li HY, Wen ZH, Zhang DK, Cui XY. Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: A systematic review and meta-analysis. Curr Ther Res Clin Exp. 2008 Jun;69(3):181-91. doi: 10.1016/j.curtheres.2008.06.009. PMID: 24692797; PMCID: PMC3969923.
Copy Download .nbib Format: NLM
Share it on

Curr Ther Res Clin Exp. 2008 Jun;69(3):181-91. doi: 10.1016/j.curtheres.2008.06.009.

Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: A systematic review and meta-analysis.

Current therapeutic research, clinical and experimental

Xin-Pu Miao, Qin Ouyang, Hui-Yan Li, Zhong-Hui Wen, De-Kui Zhang, Xiao-Yan Cui

Affiliations

  1. Department of Gastroenterology, West China Hospital of Sichuan University, Chengdu, China.
  2. Department of Chemotherapy for Cancer, West China Hospital of Sichuan University, Chengdu, China.
  3. Department of Biochemistry and Molecular Biology, West China Medical Center of Sichuan University, Chengdu, China.

PMID: 24692797 PMCID: PMC3969923 DOI: 10.1016/j.curtheres.2008.06.009

Abstract

BACKGROUND: In the general population, selective cyclooxygenase (COX)-2 inhibitors have been associated with fewer gastrointestinal adverse effects (AEs) than NSAIDs, but whether they are associated with exacerbations in patients with inflammatory bowel disease (IBD) remains controversial.

OBJECTIVE: The aim of this study was to review published and unpublished findings to determine whether the use of COX-2 inhibitors increased the risk for IBD exacerbations relative to placebo in the treatment of IBD.

METHODS: A systematic search of MEDLINE (1966-July 2007), EMBASE (1980-July 2007), the Cochrane Library (2007 Issue 4), US Food and Drug Administration records, and data on file at Novartis Pharmaceuticals Corporation, Pfizer US Pharmaceutical Group, and Merck & Co., Inc., using the search terms celecoxib, rofecoxib, valdecoxib, etoricoxib, lumiracoxib, cyclooxygenase 2 inhibitor, Crohn's disease, ulcerative colitis, and inflammatory bowel disease, was performed to identify randomized, placebo-controlled clinical trials of 5 COX-2 inhibitors in patients with IBD. The publications were fully reviewed for quality. Data on trial design, patient characteristics, intervention drugs, dosages, and outcomes were collected using a predetermined data-extraction form. A meta-analysis was performed based on the publications that met the inclusion/exclusion criteria.

RESULTS: Of 588 studies identified in the electronic search, 574 were excluded after screening the titles and abstracts. Fourteen related to the use of COX-2 inhibitors in patients with IBD were reviewed. Two randomized, controlled trials comparing COX-2 inhibitors with placebo were identified. In the first trial, 82 patients were randomized to receive etoricoxib (60-120 mg/d) and 77 to receive placebo. The exacerbation rates were 10.5% (8/76) in the active-treatment group and 11.4% (8/70) in the placebo group (relative risk [RR], 0.92; 95% CI, 0.37-2.32). In the second trial, 112 patients were treated with celecoxib (200 mg BID) and 110 received placebo. The exacerbation rates were 3.7% (4/107) in the celecoxib group and 2.7% (3/110) in the placebo group (RR, 0.73; 95% CI, 0.17-3.18). Of these patients, 5 were lost to follow-up because of AEs. In the meta-analysis comparing COX-2 inhibitors and placebo, the RR was 0.86 (95% CI, 0.39-1.88). No statistically significant differences in IBD relapse rates were found between COX-2 inhibitors and placebo.

CONCLUSIONS: The results from this meta-analysis suggest that insufficient data were available to determine the impact of COX-2 inhibitors on IBD exacerbations. The relatively smaller risk for AEs makes the short-term use of COX-2 inhibitors potentially attractive, but the long-term benefits remain unclear. Further studies with sound methodology and large sample sizes are needed to evaluate the tolerability of COX-2 inhibitors in the treatment of IBD.

Keywords: Crohn's disease; cyclooxygenase-2 inhibitor; inflammatory bowel disease; meta-analysis; ulcerative colitis

References

  1. J Clin Rheumatol. 2001 Jun;7(3):151-9 - PubMed
  2. Aliment Pharmacol Ther. 2004 Nov 15;20(10):1035-43 - PubMed
  3. Ann Intern Med. 1995 Aug 15;123(4):241-9 - PubMed
  4. Medicine (Baltimore). 1976 Sep;55(5):401-12 - PubMed
  5. Arthritis Rheum. 2005 Aug 15;53(4):510-8 - PubMed
  6. Arthritis Rheum. 2003 Nov;48(11):3102-11 - PubMed
  7. Med Clin North Am. 1990 Jan;74(1):39-50 - PubMed
  8. Am J Med. 2001 Jan 8;110(1A):33S-37S - PubMed
  9. Lancet. 2004 Aug 21-27;364(9435):665-74 - PubMed
  10. BMJ. 1997 Nov 22;315(7119):1333-7 - PubMed
  11. Am J Gastroenterol. 2002 Apr;97(4):910-4 - PubMed
  12. N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528 - PubMed
  13. J Clin Gastroenterol. 2005 Feb;39(2):142-3 - PubMed
  14. Aliment Pharmacol Ther. 2004 Apr 1;19(7):755-64 - PubMed
  15. BMJ. 1998 Aug 22;317(7157):526-30 - PubMed
  16. Am J Gastroenterol. 2002 Apr;97(4):1061-2 - PubMed
  17. Gastroenterology. 2004 May;126(6):1504-17 - PubMed
  18. Inflamm Bowel Dis. 2004 Jul;10(4):352-6 - PubMed
  19. Am J Gastroenterol. 2006 Feb;101(2):311-7 - PubMed
  20. Gastroenterology. 1993 Jun;104(6):1832-47 - PubMed
  21. Control Clin Trials. 1996 Feb;17(1):1-12 - PubMed
  22. Gastroenterol Clin Biol. 2003 May;27(5):511-3 - PubMed
  23. Am J Gastroenterol. 2001 Apr;96(4):1306-8 - PubMed
  24. Gastroenterol Clin North Am. 1999 Jun;28(2):255-81, vii - PubMed
  25. Arthritis Rheum. 2000 Jan;43(1):4-13 - PubMed
  26. Aliment Pharmacol Ther. 2003 Jun 1;17(11):1371-80 - PubMed
  27. Inflamm Bowel Dis. 2005 Nov;11 Suppl 1:S3-12 - PubMed
  28. Am J Gastroenterol. 2002 Dec;97(12):3209-10 - PubMed
  29. Mt Sinai J Med. 2002 Jan-Mar;69(1-2):105-6 - PubMed
  30. Am J Gastroenterol. 2000 Aug;95(8):1949-54 - PubMed
  31. Nat New Biol. 1971 Jun 23;231(25):232-5 - PubMed
  32. JAMA. 2000 Sep 13;284(10):1247-55 - PubMed
  33. Osteoarthritis Cartilage. 2002 Nov;10(11):836-7 - PubMed
  34. Clin Gastroenterol Hepatol. 2006 Feb;4(2):203-11 - PubMed
  35. JAMA. 1999 Nov 24;282(20):1929-33 - PubMed
  36. Clin Gastroenterol Hepatol. 2006 Feb;4(2):196-202 - PubMed
  37. Gastroenterology. 1998 Jul;115(1):182-205 - PubMed
  38. Presse Med. 2005 Mar 26;34(6):443-5 - PubMed

Publication Types